PTU - Polskie Towarzystwo Urologiczne
list of articles:

The future of overactive bladder pharmacotherapy. Part I: opioid receptors, serotoninergic system, gamma- aminobutyric acid, gabapentin, vanilloid receptors, dopaminergic system, tachykinin receptors
Article published in Urologia Polska 2007/60/1.


Tomasz Rechberger, Andrzej Wróbel
II Klinika Ginekologii Akademii Medycznej w Lublinie


urinary bladder, overactive bladder, pharmacotherapy


Identification of suitable targets for pharmacologic intervention is essential for effective treatment of overactive bladder. With the present knowledge of the central and peripheral control of micturition, sites of action and drug mechanisms that can influence bladder function can be easily identified. The problem however is not only to inhibit bladder contraction, but to eliminate overactivity without disturbing normal micturition reflex. Muscarinic receptor antagonists are the mainstay of current treatments for the overactive bladder, however these exert severe side effects that result in the discontinuation of the treatment in a significant number of patients. Thus, there is an urgent need for the new treatments acting via alternative mechanisms. The basic pathophysiology of the bladder remains poorly understood compared with other systems of the body, but our knowledge on mechanism controlling lower urinary tract is still emerging. The following article considers some of the potential therapeutic approaches that are currently under investigation.


  1. Kuhar MJ, Pert CB, Snyder SH: Regional distribution of opiate receptor binding in monkey and human brain. Nature 1973, 245, 447-450.
  2. Malinovsky M, Le Normand L, Lepage Y et al: The urodynamic effects of intravenous opioids and ketoprofen in humans. Anesth Analg 1998, 87, 456-461.
  3. Igawa Y, Andersson K-E, Post C et al: A rat model for investigation of spinal mechanisms in detrusor instability associated with infravesical outflow obstruction. Urol Res 1993, 21, 239-244.
  4. Igawa Y, Westerling D, Mattiasson A et al: Effects of morphine metabolites on micturition in normal, unanaesthetized rats. Br J Pharmacol 1993, 257-262.
  5. Kieffer BL: Opioids: first lessons from knockout mice. Trends Pharmacol Sci 1990, 20, 19-26.
  6. Raffa RB, Friderichs E: The basic science aspect on tramadol hydrochloride. Pain Reviews 1996, 249-271.
  7. Pandita RK, Pehrson R, Christoph T et al: Actions of tramadol on micturition in awake, freely moving rats. Br J Pharmacol 2003, 139, 741-748.
  8. Pehrson R, Andersson K-E: Tramadol inhibits rat detrusor overactivity caused by dopamine receptor stimulation. Urol 2003, 170: 272-275.
  9. Kakizaki H, Yoshiyama M. Koyanagi T et al: Effects of WAY100635, a selective 5-HT1A-receptor antagonist on the micturition-reflex pathway in the rat. Am J Physiol Regul Integr Comp Physiol 2001, 280, 1407-1413.
  10. Hoyer D, Clarke DE, Fozard JR et al: International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994, 46, 157-203.
  11. Thor KB, Katofiasc MA, Danuser H et al: The role of 5-HT1A - receptors in control of lower urinary tract function in cats. Brain Res 2002, 946: 290-297.
  12. Espey MJ, Downie JW: Serotonergic modulation of bladder function before and after spinal transection. Eur J Pharmacol. 1995, 287, 173-177.
  13. Thor KB, Katofiasc MA, Danuser H et al: The role of 5-HT1A receptors in control of lower urinary tract function in cats. Brain Res. 2002, 946: 290-297.
  14. Burgard EC, Fraser MO, Thor KB: Serotonergic modulation of bladder afferent pathways. Urology 2003, 62: 10-15.
  15. Espey ML, Downie LW: Serotonergic modulation of cal bladder function before and after spinal transection. Eur J Pharmacol 1995, 287, 173-177.
  16. Danuser H, Thor KB. Spinal 5-HT2 receptor-mediated facilitation of pudendal nerve reflexes in the anaesthetized cats. Br J Pharmacol 1996, 118, 150-154.
  17. Espey ML, Downie LW: Serotonergic modulation of cal bladder function before and after spinal transection. Eur J Pharmacol 1995, 287, 173-177.
  18. Little JO Jr, Kaplan SA: An unexpected association between urinary incontinence, depression and sexual dysfunction. Drugs Today 2002, 38, 777-782.
  19. Na YG, Lee KS, Klausner AP, et al: Fluoxetine reverses bladder overactivity in a rat model of endogenous depression. J Urol 2003, 169, 44.
  20. Movig KL, Leufkens HG, Belitser SV, et al: Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Ser 2002, 11, 271-279.
  21. Igawa Y, Mattiasson A, Andersson KE: Effects of GABA-receptor stimulation and blockade on micturition in normal rats and rats with bladder outflow obstruction. Urol. 1993, 150, 537-542.
  22. Blok BFM, de Weerd H, and Holstege G: The pontine micturition centre projects to sacral cord GABA immunoreactive neurons in the cat. Neurosci Lett 1997, 233, 109-112.
  23. Bushman W, Steers WD, Meythaler M: Voiding dysfunction in patients with spastic paraplegia: urodynamic evaluation and response to continuous intrathecal baclofen. Neurourol Urodyn 1993, 12, 163-170.
  24. Perucca E: The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol 1996, 42, 531-543.
  25. Chebib M, Johnston GAR: The "ABC" of GABA receptors: a brief review. Clin Exp Pharmacol Physiol 1999, 26, 937-940.
  26. Igawa Y, Mattiasson A, Andersson KE: Effects of GABA-receptor stimulation and blockade on micturition in normal rats and rats with bladder outflow obstruction. J Urol 1993: 537-542.
  27. Pehrson R, Lehmann A, Andersson KE: Effects of gamma-aminobutyrate B receptor modulation on normal micturition and oxyhemoglobin induced detrusor overactivity in female rats. J Urol 2002, 168, 2700-2705.
  28. Maggi CA, Furio M, Santicioli P, et al: Spinal and supraspinal components of GABAergic inhibition of the micturilian reflex in rats. J Pharmacol Exp Ther 1987, 240, 998-1005.
  29. Maneuf YP, Gonzalez MI, Sutton KS, et al: Cellular and molecular action of the putative GABA-mimetic, gabapentin. Cell Mol Life Sci 2003, 60, 742-750.
  30. Cruz F: Vanilloid receptor and detrusor instability. Urology 2002, 59, 51-60.
  31. Silva C, Ribeiro MJ, Cruz F: The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J Urol 168: 575-579, 2002.
  32. Palma P, Thiek M, Riccetto C, et al: Resiniferatoxin for idiopathic overactive bladder refractory to anticholinergics. Eur Urol 2003, 171.
  33. Birder LA, Kanai A, de Groat WC, et al: Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat Neurosci 2002, 5, 856-860.
  34. Cockayne DA, Hamilton SG, Zhu QM, et al: Urinary bladder hyporeflexia and reduced pain-related behavior in P2X3-deficient mice. Nature 2000, 407, 1011-1015.
  35. Vlaskovska M, Kasakov L, Rong W, et al: G. P2X3 knock-out mice reveal a major sensory role for urothelially released ATP. Neurosci 2001, 21, 5670-5677.
  36. Elneil S, Skepper JN, Kidd E, et al: Distribution of P2X (l) and P2X (3) receptors in the rat and human urinary bladder. Pharmacology 2001, 63, 120-128.
  37. Yiangou Y, Facer P, Baecker PA, et al: Capsaicin receptor VRl and ATP-gated ion channels P2X3 in human urinary bladder. BJU 2001, 87, 774-779.
  38. Zhang X, Izawa Y, lshizuka O, et al: Effects of resiniferatoxin desensitization of capsaicin-sensitive afferents on detrusor over-activity induced by intravesical capsaicin, acetic acid or ATP in conscious rats. Naunyn Schmiedebergs Arch Pharmacol 2003, 367, 473-479.
  39. Yoshimura N, Mizuta E, Kuno S, et at: The dopamine Dl receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP). Neuropharmacology. 1993, 32, 315-321.
  40. de Groat WC, and Yoshimura N. Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol 2001, 41, 691-721.
  41. Seki S, Igawa Y, Kaidoh K, et al: Role of dopamine Dl and D2 receptors in the micturition reflex in conscious rats. Neurourol Urodyn. 2001, 20, 105-113.
  42. Lincoln and Burnstock G: Autonomic innervation of the urinary bladder and urethra, in Maggi CA (red): The Autonomic Nervous System. London, Harvood Academic Publishers. 1993, 33-68.
  43. Maggi CA: Tachykinins and calcitonin gene-related peptide (CGRP) as co-transmiters released from peripheral endings of sensory nerves. PTOG Neurobiol. 1995, 45, 1-98.
  44. Palea S, Corsi M, Anibani L et al: Pharmacological characterization of tachykinin NK, receptors on isolated human urinary bladder, prostatic urethra and prostate. J Pharmacol Exp Ther. 1996, 277, 700-705.


Tomasz Rechberger
II Klinika Ginekologii AM
20-090 Lublin
ul. Jaczewskiego 8
tel. 0691 376 307